



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Dated: 24th September, 2021

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Sub: Intimation U/R 30 of the SEBI (LODR) Regulations 2015- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited ties up with Cadila Healthcare Ltd for production of ZyCoV-D vaccine

Dear Madam/Sir,

This is to inform you that Shilpa Medicare Limited ('SML' or 'the Company'), via its wholly owned subsidiary, Shilpa Biologicals Pvt Ltd (SBPL), has entered into a definitive agreement with Cadila Healthcare Ltd (CHL) for production-supply of the ZyCoV-D vaccine drug substance from its integrated Biologics R&D cum Manufacturing center at Dharwad, Karnataka.

The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties.

ZyCoV-D is the first DNA plasmid vaccine in the world for human use developed indigenously by CHL against the Covid-19 virus. It is also the first COVID-19 vaccine for adolescents in the 12-18 age group, besides the adult population and is a needle-free vaccine administered using The PharmaJet® a needle free applicator, which ensures painless intradermal vaccine delivery. CHL will transfer the ZyCoV-D technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the Drug substance of the vaccine, while CHL is responsible for filling/packaging/distribution/marketing of the vaccine in its marketing territories.

The biologics business has been identified as a strategic growth engine by SML and it has made significant investments in setting up a high end, flexible biologics facility in SBPL. This facility at Dharwad would cater to the requirements of the fast-growing biologics field, that include the DNA vaccine, adenoviral, subunit vaccines, monoclonal antibodies & fusion proteins.

This is for your information and doing the needful.

With regards
For and on behalf of
Shilpa Medicare Limited

V V Krishna Chaitanya
Company Secretary & Compliance officer